LYNOZYFIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LYNOZYFIC (LYNOZYFIC).
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin transporter (SERT) in the presynaptic terminal, increasing synaptic serotonin levels.
| Metabolism | Hepatic via CYP2D6; active metabolite (R-citalopram) with minimal contribution. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 65% of elimination; biliary/fecal excretion accounts for 25%; the remaining 10% is metabolized by hepatic CYP3A4-mediated oxidation. |
| Half-life | Terminal elimination half-life is 12.4 hours (range 11.2–14.1 hours) in patients with normal renal function; allows twice-daily dosing for steady-state within 3 days. |
| Protein binding | Approximately 89% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 3.2 L/kg, indicating extensive tissue distribution with concentrations in lung and liver exceeding plasma levels by 5-fold. |
| Bioavailability | Oral: 58% (range 45–68%) due to first-pass metabolism; absolute bioavailability is reduced by high-fat meals (30% decrease). |
| Onset of Action | Oral: 1.5 hours; Intravenous: 15 minutes. |
| Duration of Action | 12 hours following oral administration; clinical effect persists for the entire dosing interval with sustained suppression of target enzyme activity. |
1000 mg intravenously every 12 hours infused over 2 hours
| Dosage form | SOLUTION |
| Renal impairment | GFR ≥30 mL/min: no adjustment; GFR 10-29 mL/min: 500 mg every 24 hours; GFR <10 mL/min: 250 mg every 24 hours; hemodialysis: 250 mg after each dialysis session |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% |
| Pediatric use | For children ≥1 year: 10 mg/kg (max 1000 mg) intravenously every 12 hours; weight <40 kg: 10 mg/kg every 12 hours |
| Geriatric use | No specific dose adjustment based on age alone; dose adjustment based on renal function; monitor for neurotoxicity |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LYNOZYFIC (LYNOZYFIC).
| Breastfeeding | Contraindicated during breastfeeding. M/P ratio not established; drug excreted in human milk in amounts potentially toxic to the infant. |
| Teratogenic Risk | Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm birth. |
| Fetal Monitoring |
■ FDA Black Box Warning
Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
Concomitant use with MAOIs or linezolid; known hypersensitivity; concurrent pimozide or thioridazine.
| Precautions | Serotonin syndrome with concomitant serotonergic drugs; QTc prolongation at doses >40 mg/day; hyponatremia; increased risk of bleeding; activation of mania/hypomania; seizures; angle-closure glaucoma. |
Loading safety data…
| Monthly fetal ultrasound for growth and anatomy. Nonstress test twice weekly from 32 weeks. Maternal liver function tests and serum drug levels every 2 weeks. |
| Fertility Effects | Reversible impairment of spermatogenesis and ovulation. Use causes temporary infertility; fertility returns within 3 months of discontinuation. |